Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery

被引:0
|
作者
Li, Qingxin [1 ]
Kang, Congbao [2 ]
机构
[1] Guangdong Acad Sci, Inst Biol & Med Engn, Guangdong Prov Engn Lab Biomass High Value Utiliza, Guangzhou 510316, Peoples R China
[2] ASTAR, Expt Drug Dev Ctr EDDC, 10 Biopolis Rd,05-01, Singapore 138670, Singapore
来源
MOLECULES | 2024年 / 29卷 / 23期
关键词
F-19-NMR; fragment screening; drug discovery; fragment-based drug design; in-cell F-19-NMR; OBSERVED FLUORINE NMR; PROTEIN-PROTEIN INTERACTIONS; LIGAND BINDING; STD NMR; RNA; SPECTROSCOPY; IDENTIFICATION; TOOL; QUANTIFICATION; VALIDATION;
D O I
10.3390/molecules29235748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fragment-based drug discovery is a powerful approach in drug discovery, applicable to a wide range of targets. This method enables the discovery of potent compounds that can modulate target functions, starting from fragment compounds that bind weakly to the targets. While biochemical, biophysical, and cell-based assays are commonly used to identify fragments, F-19-NMR spectroscopy has emerged as a powerful tool for exploring interactions between biomolecules and ligands. Because fluorine atoms are not naturally present in biological systems, F-19-NMR serves as a sensitive method for fragment screening against diverse targets. Herein, we reviewed the applications of F-19-NMR in fragment screening, highlighting its effectiveness in identifying fragments that bind weakly to various targets such as proteins and RNA. The accumulated evidence suggests that F-19-NMR will continue to be a crucial tool in drug discovery.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Fragonomics: fragment-based drug discovery
    Zartler, ER
    Shapiro, MJ
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (04) : 366 - 370
  • [22] Current perspectives in fragment-based ligand discovery
    Hubbard, Roderick
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2015, 71 : S37 - S37
  • [23] Fragment Based Drug Discovery: Practical Implementation Based on 19F NMR Spectroscopy
    Jordan, John B.
    Poppe, Leszek
    Xia, Xiaoyang
    Cheng, Alan C.
    Sun, Yax
    Michelsen, Klaus
    Eastwood, Heather
    Schnier, Paul D.
    Nixey, Thomas
    Zhong, Wenge
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (02) : 678 - 687
  • [24] Strategies and experiences in fragment-based drug discovery
    Hubbard, Roderick E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 510 - 510
  • [25] Fragment-based drug discovery: Less is more
    Heightman, Tom D.
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Is it time for biocatalysis in fragment-based drug discovery?
    Ramsden, Jeremy I.
    Cosgrove, Sebastian C.
    Turner, Nicholas J.
    CHEMICAL SCIENCE, 2020, 11 (41) : 11104 - 11112
  • [27] Recent developments in fragment-based drug discovery
    Congreve, Miles
    Chessari, Gianni
    Tisi, Dominic
    Woodhead, Andrew J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) : 3661 - 3680
  • [28] Case Studies in Fragment-Based Drug Discovery
    Howard, Steven
    JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (07) : 870 - 870
  • [29] Fragment-based Drug Discovery: Concept and Aim
    Tanaka, Daisuke
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 315 - 323
  • [30] Fragment-Based Drug Discovery for RNA Targets
    Lundquist, Kasper P.
    Panchal, Vipul
    Gotfredsen, Charlotte H.
    Brenk, Ruth
    Clausen, Mads H.
    CHEMMEDCHEM, 2021, 16 (17) : 2588 - 2603